Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.60 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27324025 | 0.88 | CRBN (0.47) | CRBNSRD5A1CSNK1A1HTR2AHTR2C | |
| SCHEMBL26107723 | 0.86 | CRBN (0.58) | CRBNSRD5A1CSNK1A1IKZF2DDB1 | |
| SCHEMBL31347063 | 0.86 | CRBN (0.58) | CRBNSRD5A1CSNK1A1IKZF2DDB1 | |
| SCHEMBL23173151 | 0.86 | CRBN (0.61) | CRBNCSNK1A1IKZF2DDB1 | |
| SCHEMBL26248446 | 0.86 | CRBN (0.46) | CRBNSRD5A1CSNK1A1HTR2AHTR2C | |
| SCHEMBL27097398 | 0.84 | CRBN (0.59) | CRBNSRD5A1CSNK1A1HTR2AHTR2C | |
| SCHEMBL24745571 | 0.84 | CRBN (0.56) | CRBNCSNK1A1IKZF2DDB1 | |
| SCHEMBL824532 | 0.83 | CRBN (0.63) | CRBNSRD5A1HTR2AHTR2CHTR2B | |
| SCHEMBL30121132 | 0.83 | CRBN (0.63) | CRBNSRD5A1HTR2AHTR2CHTR2B | |
| SCHEMBL26075169 | 0.82 | CRBN (0.57) | CRBNIKZF2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230242508-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230056205-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056205-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | DHPS, QDPR, HTR5A | CRBN 2185/4885SRD5A1 212/4885CSNK1A1 3164/4885 |
| US-20230242508-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | CRBN 119/4885SRD5A1 3885/4885CSNK1A1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.